Leading pharmaceutical executive brings over 4 decades of commercial, M&A, and governance leadershipHOUSTON, July 15, 2026 (GLOBE NEWSWIRE) -- RadioMedix, Inc., a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and cancer therapy, today announced the appointment of Brian A. Markison to the company’s board of directors effective July 1, 2026. "We are thrilled to welcome Brian to our Board as our second independent Director. He br

What a fantastic six months it’s been for Lantheus. Shares of the company have skyrocketed 60.5%, hitting $105.30. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.